{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:30:11Z","timestamp":1786483811514,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"The Amgen Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.dld.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:04:31Z","timestamp":1777662271000},"page":"966-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet\/triplet chemotherapy: ENGIC 01 \u2013 PRODIGE 107 \u2013 FFCD 2306 \u2013 COLOSOTO trial"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-891X","authenticated-orcid":false,"given":"Adrien","family":"Grancher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-5840","authenticated-orcid":false,"given":"Matteo","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexej","family":"Ballhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-2001","authenticated-orcid":false,"given":"Rosario","family":"Vidal Tocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3450","authenticated-orcid":false,"given":"Annabel","family":"Alig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Taravella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Soularue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Guarssifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Pelkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kochen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Delliponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik Paul","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2026.04.009_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2026.04.009_bib0002","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdy033","article-title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","volume":"29","author":"Malvezzi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0003","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"Cremolini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0004","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with Cetuximab or Bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.04.009_bib0005","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs Bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2026.04.009_bib0006","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.04.009_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.04.009_bib0008","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S1470-2045(11)70199-1","article-title":"Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial","volume":"12","author":"Ducreux","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.04.009_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/annonc\/mdn638","article-title":"Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer","volume":"20","author":"Cunningham","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdv491","article-title":"Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)","volume":"27","author":"Aparicio","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0012","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0013","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1200\/JCO.23.00506","article-title":"Initial Panitumumab plus Fluorouracil, Leucovorin, and Oxaliplatin or plus Fluorouracil and Leucovorin in elderly patients with RAS and BRAF wild-type metastatic colorectal cancer: the PANDA Trial by the GONO foundation","volume":"41","author":"Lonardi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0014","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0016","first-page":"581","article-title":"Prognostic significance of KRAS gene mutations in colorectal cancer\u2013preliminary study","volume":"7","author":"Dinu","year":"2014","journal-title":"J Med Life"},{"key":"10.1016\/j.dld.2026.04.009_bib0017","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1111\/cas.16262","article-title":"Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation","volume":"115","author":"Ugai","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.dld.2026.04.009_bib0018","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4161\/cbt.28550","article-title":"Characterization of rare transforming KRAS mutations in sporadic colorectal cancer","volume":"15","author":"Tong","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.dld.2026.04.009_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.dld.2026.04.009_bib0020","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of Adagrasib plus Cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dld.2026.04.009_bib0021","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2026.04.009_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","article-title":"Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial","volume":"30","author":"Kuboki","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2026.04.009_bib0024","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C\u2013mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105055","article-title":"Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative","volume":"10","author":"Taieb","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.04.009_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.dld.2026.04.009_bib0027","article-title":"Comprehensive clinical and molecular characterization of KRAS G12C-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0028","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/cancers16081515","article-title":"First-line LV5FU2 with or without Aflibercept in patients with non-resectable metastatic colorectal cancer: a randomized phase II trial (PRODIGE 25-FFCD-FOLFA)","volume":"16","author":"Legoux","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.dld.2026.04.009_bib0029","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0031","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO-24-02026","article-title":"Overall survival analysis of the phase III CodeBreaK 300 study of Sotorasib plus Panitumumab versus investigator\u2019s choice in chemorefractory KRAS G12C colorectal cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.04.009_bib0032","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(25)00352-3","article-title":"Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial","volume":"26","author":"Modest","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826007164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:54:09Z","timestamp":1786481649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826007164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1590865826007164"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.009","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet\/triplet chemotherapy: ENGIC 01 \u2013 PRODIGE 107 \u2013 FFCD 2306 \u2013 COLOSOTO trial","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}